$267.14
Value $644B
JNJ and TMCI stock compared: price, dividend, valuation and results, from SEC filings.
$267.14
Value $644B
$4.35
Value $281M
Johnson & Johnson (JNJ) has a market value of $644B and Treace Medical Concepts (TMCI) $281M. Over the last year, with dividends, JNJ moved +36.6% and TMCI +55.9%. Dividend yield: JNJ 1.98%, TMCI none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
JNJ$644B
TMCI$281M
JNJ is 2,291 times TMCI
Revenue, 12 months
JNJ$99.3B
TMCI$203M
JNJ is 489 times TMCI
Net income, 12 months
JNJ$16.1B
TMCI-$56M
Operating margin
JNJ–
TMCI-24.4%
ROIC
JNJ12.4%
TMCI-29.1%
41.5 points apart
P/E
JNJ40.0
TMCI–
Dividend yield
JNJ2.0%
TMCI0.0%
2.0 points apart
5-year return
JNJ+89.1%
TMCI-77.3%
166.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
JNJ+89.1%
TMCI-77.3%
| Period | JNJWith dividends | TMCIWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | +36.6%Price +33.6% | +55.9%Price +55.9% |
| 3 years since November 17, 2023 | +94.2%+24.8% a yearPrice +78.3% | -48.5%-19.8% a yearPrice -48.5% |
| 5 years since November 18, 2021 | +89.1%+13.6% a yearPrice +64.5% | -77.3%-25.7% a yearPrice -77.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
JNJJohnson & JohnsonTMCITreace Medical Concepts
| Price | $267.14 | $4.35 |
|---|---|---|
| Market value | $644B | $281M |
| Enterprise value (EV) | $671B | – |
| P/E | 40.0 | – |
| P/E, 5-year median | 21.9 | – |
| P/B | 7.9 | 4.6 |
| EV/EBIT | 37.8 | – |
| Free cash flow yield | 3.2% | – |
| Revenue, 12 months | $99.3B | $203M |
|---|---|---|
| Net income, 12 months | $16.1B | -$56M |
| Free cash flow, 12 months | $20.6B | -$19M |
| Earnings per share, 12 months | $6.59 | -$0.85 |
| Revenue growth, year on year | 6.1% | 1.6% |
| Revenue growth a year, past | +2.7%over 5 years | +30.0%over 5 years |
| EPS growth a year, past | +14.9%over 5 years | – |
| Gross margin | 67.6% | 79.6% |
|---|---|---|
| Operating margin | – | -24.4% |
| Net margin | 16.2% | -27.4% |
| ROIC | 12.4% | -29.1% |
| ROE | 19.7% | -72.8% |
| Cash | $17.2B | $40M |
|---|---|---|
| Total debt | $44.7B | – |
| Net debt / EBITDA | 1.1 | – |
| Interest cover | 18.0× | -8.2× |
| Dividend yield | 2.0% | – |
|---|---|---|
| Dividend per share, 12 months | $5.28 | – |
| Dividend growth a year, past | +5.3%over 5 years | – |
| Buyback yield | 0.9% | – |
| Shareholder yield | 2.9% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($644B) is about 2,291.3 times Treace Medical Concepts ($281M), at today's prices.
Since November 18, 2021, JNJ's price moved +64.5% and TMCI's -77.3%. With dividends: JNJ +89.1% (+13.6% a year), TMCI -77.3% (-25.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is 1.98% for Johnson & Johnson and none for Treace Medical Concepts. Over the last twelve months they paid $5.28 and – per share.
Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and -27.4% for Treace Medical Concepts, and the operating margin – and -24.4%. Revenue was $99.3B and $203M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.